A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
include a safe harbor for communication of information 
with respect to a vaccine authorized for emergency use 
under such Act that is provided or distributed to a 
health care provider, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
03:14 Jun 26, 2021
H3705
2 
•HR 3705 IH
SECTION 1. SAFE HARBOR FOR COMMUNICATIONS ABOUT 
1
VACCINES AUTHORIZED FOR EMERGENCY 
2
USE. 
3
(a) IN GENERAL.—The Federal Food, Drug, and 
4
Cosmetic Act is amended by inserting after section 502 
5
(21 U.S.C. 352) the following: 
6
‘‘SEC. 502A. SAFE HARBOR FOR COMMUNICATIONS ABOUT 
7
VACCINES AUTHORIZED FOR EMERGENCY 
8
USE. 
9
‘‘(a) IN GENERAL.—The communication of informa-
10
tion (through written or oral means), described in sub-
11
section (b), with respect to the use of a vaccine authorized 
12
for emergency use under section 564 provided or distrib-
13
uted to a covered health care entity shall not be a basis 
14
for treating such vaccine as, or be treated as evidence that 
15
such vaccine is— 
16
‘‘(1) misbranded under subsection (a) or (f) of 
17
section 502; or 
18
‘‘(2) in violation of section 505 or 564 of this 
19
Act or subsection (a) or (k) of section 351(a)(1) of 
20
the Public Health Service Act, as applicable. 
21
‘‘(b) INFORMATION DESCRIBED.—Information de-
22
scribed in this subsection is any information relating to 
23
a use of a vaccine authorized for emergency use under sec-
24
tion 564 within the scope of that authorization that— 
25
03:14 Jun 26, 2021
H3705
3 
•HR 3705 IH
‘‘(1) is neither false nor misleading, when meas-
1
ured objectively against the information available at 
2
the time the statement is made; 
3
‘‘(2) is accompanied, as required, by an appro-
4
priate disclaimer, including— 
5
‘‘(A) a statement identifying any dif-
6
ferences between the information and any au-
7
thorized labeling of the vaccine; 
8
‘‘(B) a statement identifying contradictory 
9
evidence; and 
10
‘‘(C) such other information as may be re-
11
quired by regulation; and 
12
‘‘(3) is based on competent and reliable sci-
13
entific evidence, as described in subsection (e). 
14
‘‘(c) COVERAGE NOT EXCLUDED.—The distribution 
15
of information that otherwise meets the requirements of 
16
this section shall not fail to meet the requirements of sub-
17
section (a) because the manufacturer or distributor of the 
18
vaccine about which information is being distributed has— 
19
‘‘(1) knowledge that such vaccine is being used 
20
by patients or health care practitioners in a manner 
21
not described in any authorized labeling of the vac-
22
cine, as applicable; or 
23
03:14 Jun 26, 2021
H3705
4 
•HR 3705 IH
‘‘(2) objective or subjective intent that such 
1
vaccine be used in a manner inconsistent with any 
2
labeling, as applicable, of such vaccine. 
3
‘‘(d) RULE OF CONSTRUCTION.—Nothing in this sec-
4
tion shall be construed— 
5
‘‘(1) to limit communication to which this sec-
6
tion does not specifically apply; or 
7
‘‘(2) to alter or expand the authority of the Sec-
8
retary to enforce the provisions of this Act of section 
9
351 of the Public Health Service Act, except with 
10
respect to the communication of information to 
11
which this section specifically applies. 
12
‘‘(e) DEFINITIONS.—In this section: 
13
‘‘(1) COMPETENT
AND
RELIABLE
SCIENTIFIC 
14
EVIDENCE.— 
15
‘‘(A) IN
GENERAL.—In this section, the 
16
term ‘competent and reliable scientific evidence’ 
17
means evidence established through scientific 
18
methods that are widely accepted by experts in 
19
the relevant field and followed pursuant to a 
20
clear and well-described protocol, as scientif-
21
ically appropriate, regardless of whether such 
22
evidence is supported by 2 adequate and well- 
23
controlled clinical studies. 
24
03:14 Jun 26, 2021
H3705
5 
•HR 3705 IH
‘‘(B) INCLUSIONS.—Such term may in-
1
clude information— 
2
‘‘(i) derived from clinical trials, obser-
3
vational studies, clinical studies or bench 
4
tests that describe performance, database 
5
reviews, registries, patient utilization pro-
6
jections, and modeling techniques, and the 
7
data, inputs, and components of such in-
8
formation; 
9
‘‘(ii) about the effects of a vaccine in 
10
subgroups defined by demographic or other 
11
variables, including groups defined by race, 
12
sex, risk factors, or other variables, such 
13
as genomic features or disease severity; 
14
‘‘(iii) related to the authorization for 
15
emergency use under section 564, as appli-
16
cable; and 
17
‘‘(iv) relating to the safety, effective-
18
ness, or benefit of a use or treatment that 
19
is authorized for emergency use under sec-
20
tion 564 for a vaccine, including informa-
21
tion regarding— 
22
‘‘(I) health outcomes, patient or 
23
caregiver experience, or other quality 
24
metrics; and 
25
03:14 Jun 26, 2021
H3705
6 
•HR 3705 IH
‘‘(II) the comparative effective-
1
ness of a vaccine relative to other 
2
products, other health care interven-
3
tions, program and quality improve-
4
ment interventions, or no intervention. 
5
‘‘(2) COVERED
HEALTH
CARE
ENTITY.—The 
6
term ‘covered health care entity’ means a health 
7
care provider, health care institution, payor, for-
8
mulary committee, or other similar entity carrying 
9
out responsibilities for making drug coverage, reim-
10
bursement, or usage decisions on a population 
11
basis.’’. 
12
Æ 
03:14 Jun 26, 2021
H3705
